A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

NCT00907205 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors
Cancer
Solid Cancers

Interventions

DRUG: SF1126

Sponsor

Semafore Pharmaceuticals

Collaborators

[object Object]